This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
genetics: Archive
Top 3 Genomics Stocks to Consider for Your Portfolio
by Ekta Bagri
Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.
ILMNPositive Net Change PACBPositive Net Change EDITPositive Net Change NTLAPositive Net Change CRSPPositive Net Change SANAPositive Net Change
biotechnology gene-editing genetics genomics medical pharmaceuticals
Demographic Megatrend: Stocks Poised to Benefit From Global Aging
by Urmimala Biswas
Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.
BSXNegative Net Change AMGNNegative Net Change EWPositive Net Change OHIPositive Net Change ABBVNegative Net Change CTREPositive Net Change ENSGNegative Net Change
biotechs cell-therapy gene-therapy genetics genomics healthcare hospitals medical medical-devices
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
by Ekta Bagri
GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.
ILMNPositive Net Change BEAMPositive Net Change WVEPositive Net Change CRSPPositive Net Change TWSTPositive Net Change WGSPositive Net Change
biotechnology biotechs gene-editing genetics genomics medical pharmaceuticals
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
by Ekta Bagri
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech
ILMNPositive Net Change BEAMPositive Net Change EDITPositive Net Change NTLAPositive Net Change PRMEPositive Net Change CRSPPositive Net Change
biotechnology biotechs gene-editing gene-therapy genetics genomics medical pharmaceuticals
3 Promising Genomics Stocks to Keep an Eye On in 2025
by Ekta Bagri
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
BEAMPositive Net Change NTLAPositive Net Change KRYSPositive Net Change MGTXPositive Net Change
cell-therapy gene-therapy genetics genomics medical pharmaceuticals
3 Highly Ranked Medical Stocks to Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX,
by Shaun Pruitt
These highly ranked medical stocks have the value and essential services that investors may be looking for as tariff concerns and geopolitical tensions have started to rattle markets.
JAZZNegative Net Change PCRXNegative Net Change OPCHNegative Net Change
earnings genetics investing medical medical-devices pharmaceuticals
Bull of the Day: NVIDIA (NVDA)
by Kevin Cook
Owner of GPU architecture market accelerates "AI for everyone" with massive growth for years to come
NVDAPositive Net Change CDNSPositive Net Change
artificial-intelligence gene-editing genetics genomics semiconductor smart-health software
Bear of the Day: Micron (MU)
by Kevin Cook
The "megalodon of memory" is vital to the AI revolution in mobile, autos, robotics, & medicine
MUNegative Net Change NVDAPositive Net Change
artificial-intelligence automation autonomous-vehicles blockchain cloud-computing electric-vehicles genetics robotics semiconductor
2 Medical Stocks to Buy Before Earnings
by Shaun Pruitt
Cardinal Health (CAH) and Ligand Pharmaceuticals (LGND) are two healthcare companies that investors certainly want to watch going into their quarterly reports.
CAHNegative Net Change LGNDNegative Net Change
biotechnology earnings genetics medical pharmaceuticals
Time to Buy Cigna or Regeneron Stock Before Earnings?
by Shaun Pruitt
Among the Finance and Medical sector, Cigna (CI) and Regeneron Pharmaceuticals (REGN) are both leaders in their respective industries and have had strong performances over the last year as the broader market and economy declined.
REGNNegative Net Change CINegative Net Change
biotechnology earnings finance genetics insurance investing medical
BioPharma Giants Print Fresh All-Time Highs
by Bryan Hayes
The trend is our friend in this market, and these two biopharmaceutical stocks are trending exceptionally well.
REGNNegative Net Change BMYPositive Net Change
biotechnology cancer cell-therapy coronavirus earnings genetics hospitals immuno-therapy investing large-cap medical medical-devices pharmaceuticals
Bull of the Day: Pfizer Inc. (PFE)
by Bryan Hayes
With a dividend yield of 3% and a top Zacks VGM score of 'A', it's not hard to see why PFE is a top stock pick.
PFEPositive Net Change
biotechnology biotechs cancer cell-therapy coronavirus dividend-investing dividends earnings genetics hospitals immuno-therapy investing large-cap medical oncology-screening pharmaceuticals vaccines
Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength
by Bryan Hayes
3 Biopharma Stocks Displaying Relative Strength Heading Into 2022
REGNNegative Net Change GILDNegative Net Change CDMOPositive Net Change
biotechnology biotechs cancer cell-therapy coronavirus earnings gene-therapy genetics hospitals immuno-therapy investing medical oncology-screening pharmaceuticals smart-health vaccines
What History Shows Us About 2022 Market Returns
by Bryan Hayes
What to Expect From the Markets In 2022
EWPositive Net Change MLABPositive Net Change SRTSPositive Net Change
biotechnology earnings genetics investing medical medical-devices pharmaceuticals smart-health
Bull Of The Day: Cutera (CUTR)
by Brian Bolan
This maker of lasers is posting some impressive growth and earnings numbers.
earnings genetics medical medical-devices
Bull of the Day: Vertex Pharmaceuticals (VRTX)
by Kevin Cook
Scientific innovation in the treatment of cystic fibrosis bolsters success and pipeline confidence
VRTXNegative Net Change MRNAPositive Net Change CRSPPositive Net Change
biotechnology cell-therapy crispr genetics medical
Bear of the Day: NeoGenomics (NEO)
by Kevin Cook
Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff
NEOPositive Net Change EXASNegative Net Change NVTAPositive Net Change NTRAPositive Net Change GHPositive Net Change
biotechs cancer genetics genomics medical
Bear of the Day: Vericel (VCEL)
by Kevin Cook
Restoring cartilage in sports medicine and rebuilding skin after severe burns gave this small-cap big upside
VCELNegative Net Change UNHNegative Net Change MDWDPositive Net Change
biotechs genetics medical
Bull of the Day: Exact Sciences (EXAS)
by Kevin Cook
EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year
EXASNegative Net Change ADPTPositive Net Change NVTAPositive Net Change NTRAPositive Net Change GHPositive Net Change
cancer coronavirus genetics genomics
A Comprehensive Guide to Genomic ETFs
by Sweta Jaiswal, FRM
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
BEAMPositive Net Change EDITPositive Net Change PBENegative Net Change NTLAPositive Net Change CRSPPositive Net Change ARKGPositive Net Change GNOMPositive Net Change IDNAPositive Net Change
biotechs etfs genetics
Genomics ETFs Surge on a Major Breakthrough in CRISPR Study
by Sweta Jaiswal, FRM
The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
REGNNegative Net Change BEAMPositive Net Change EDITPositive Net Change NTLAPositive Net Change CRSPPositive Net Change ARKGPositive Net Change GNOMPositive Net Change IDNAPositive Net Change
etfs genetics
Bear of the Day: Guardant Health (GH)
by Kevin Cook
Cancer detection innovator with liquid biopsy saw analysts slash estimates as R&D investment costs rise
GHPositive Net Change EXASNegative Net Change
cancer genetics genomics medical
Moving Average Crossover Alert: Passage Bio (PASG)
by Zacks Equity Research
Passage Bio (PASG) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
PASGPositive Net Change
genetics medical
Bear of the Day: CRISPR Therapeutics (CRSP)
by Kevin Cook
Gene editors got a big boost recently from sickle cell potential and Cathie Wood's thematic investing
CRSPPositive Net Change EDITPositive Net Change ARKKPositive Net Change NTLAPositive Net Change ARKGPositive Net Change
biofuels cancer genetics genomics medical
Bear of the Day: Illumina (ILMN)
by Kevin Cook
Maker of premier next-gen genomic sequencing technology lowers guidance but shares make new highs
ILMNPositive Net Change EDITPositive Net Change NVTAPositive Net Change ARKKPositive Net Change ARKGPositive Net Change
biotechs coronavirus genetics genomics